FENOFIBRATE (fenofibrate) by Aurobindo Pharma is peroxisome proliferator-activated receptor alpha agonists [moa]. Approved for peroxisome proliferator receptor alpha agonist [epc]. First approved in 2022.
Drug data last refreshed 20h ago
Peroxisome Proliferator-activated Receptor alpha Agonists
Peroxisome Proliferator Receptor alpha Agonist
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Choline Fenofibrate and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia
Fenofibrate for Prevention of DR Worsening
Fenofibrate for Patients With COVID-19 Requiring Hospitalization
Cinical Trial to Explore the Efficacy of Statin/Choline Fenofibrate Combination Therapy vs Statin Monotherapy in Patients With Inadequately Controlled TG Despite Receiving Statin Monotherapy
Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function
Worked on FENOFIBRATE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.